Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data

Last Updated: October 19, 2021

This table describes only clinical trials that have evaluated anti-SARS-CoV-2 mAbs for the treatment of COVID-19. Please refer to the Prevention of SARS-CoV-2 Infection section for a discussion of clinical trials that have evaluated anti-SARS-CoV-2 mAbs for PEP of SARS-CoV-2 infection.

Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data
Table 3a. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Data

References

  1. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. 2021. Available at: https://www.fda.gov/media/145802/download.
  2. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate COVID-19. N Engl J Med. 2021;385(15):1382-1392. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34260849.
  3. Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N Engl J Med. 2021. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34587383.
  4. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early COVID-19 treatement with SARS-CoV-2 neutralizing antibody sotrovimab. medRxiv. 2021;Preprint. Available at: https://www.medrxiv.org/content/10.1101/2021.05.27.21257096v1.full.